SCHEMBL467747

SCHEMBL467747

CN1CCC(c2ccc(Nc3nc(N)nn3-c3cc4c(nn3)-c3ccccc3CCC4)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 11/20 0.53
KIT P10721 2/20 0.53
FLT3 P36888 2/20 0.53
KDR P35968 2/20 0.53
AURKA O14965 1/20 0.53
EGFR P00533 1/20 0.53
RET P07949 1/20 0.53
MET P08581 1/20 0.53
SRC P12931 1/20 0.53
PDGFRA P16234 1/20 0.53
TYRO3 Q06418 1/20 0.53
DDR1 Q08345 1/20 0.53
MERTK Q12866 1/20 0.53
AURKB Q96GD4 1/20 0.53
ALK Q9UM73 1/20 0.53
MAP4K1 Q92918 4/20 0.38
INSR P06213 1/20 0.36
JAK2 O60674 2/20 0.36
JAK3 P52333 2/20 0.36
PTK2 Q05397 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1639731 0.86 AXL (0.70) AXLKITFLT3KDRAURKA
SCHEMBL30090836 0.84 AXL (0.58) AXLKITFLT3KDRAURKA
SCHEMBL467962 0.84 AXL (0.58) AXLKITFLT3KDRAURKA
SCHEMBL467824 0.82 AXL (0.77) AXLKITFLT3KDRAURKA
SCHEMBL30121612 0.82 AXL (0.77) AXLKITFLT3KDRAURKA
SCHEMBL467825 0.82 AXL (0.77) AXLKITFLT3KDRAURKA
SCHEMBL467608 0.82 AXL (0.74) AXLKITFLT3KDRAURKA
SCHEMBL467730 0.82 AXL (0.75) AXLKITFLT3KDRAURKA
SCHEMBL468644 0.82 AXL (0.61) AXLKITFLT3KDRAURKA
SCHEMBL467927 0.81 AXL (0.60) AXLKITFLT3KDRAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2387395-A1 AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER Rigel Pharmaceuticals, Inc. (US) 2011-11-23 EP disclosed
US-8040491-B2 Exposure method, substrate stage, exposure apparatus, and device manufacturing method NIKON CORPORATION (JP) 2011-10-18 US disclosed
WO-2010083465-A1 AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER RIGEL PHARMACEUTICALS, INC. (US) 2010-07-22 WO disclosed